DMX 250

Drug Profile

DMX 250

Alternative Names: Angiotensin receptor blocker/propagermanium; DMX-250; Propagermanium/angiotensin receptor blocker

Latest Information Update: 05 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dimerix Bioscience
  • Class Organometallic compounds; Small molecules
  • Mechanism of Action Angiotensin receptor antagonists; CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Non-alcoholic steatohepatitis

Highest Development Phases

  • Preclinical Non-alcoholic steatohepatitis

Most Recent Events

  • 05 Aug 2016 DMX 250 is available for licensing as of 05 Aug 2016. http://dimerix.com/
  • 27 Jul 2016 Preclinical trials in Non-alcoholic steatohepatitis in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top